Navigation Links
Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
Date:8/3/2010

ch which may include a combination of behavior modification and pharmacotherapy," said Thomas Wadden, Ph.D., lead investigator and Professor of Psychology in Psychiatry at the University of Pennsylvania School of Medicine and Director of the Center for Weight and Eating Disorders.  "This study clearly demonstrates that when Contrave is added to a state of the art diet and exercise regimen, patients can achieve significant incremental weight loss."  

Results showed that the addition of Contrave to intensive behavior modification was also associated with statistically significant greater improvements in markers of cardiometabolic risk, including waist circumference, triglycerides, high density lipoprotein (HDL) cholesterol and fasting insulin.  The most common adverse events included nausea, headache, constipation and dizziness.  Observed adverse events were, in general, consistent with the other studies within the COR program and with the safety profile of the constituent components.

"Medication alone may not be the answer for the majority of obese patients, so it's important that we understand the benefits of a multi-modal weight loss program," said Michael Narachi, CEO of Orexigen.  "The results from this study reinforce our belief that a weight management strategy, addressing both the biological and behavioral drivers of obesity, can be successful."

Study Design

COR-BMOD was a 56-week placebo-controlled, double-blind, randomized trial that enrolled overweight and obese adults.  A total of 793 patients were randomized to receive either Contrave32 + BMOD or placebo + BMOD in a 3:1 ratio.  Nine sites in the United States participated in the study.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
4. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
5. Cornerstone Therapeutics Announces Collaboration with The Cough Company
6. Hepatitis C Therapeutics Market - Taiwan
7. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
8. Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics
9. MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
10. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
11. Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Yesterday, former Congressman ... device manufacturing facility. Rep. Kennedy and Dick ... facilitate cutting-edge research in neurological disease and treatment. ... health advocate, Garen Staglin , created One ... fundamental changes that will radically accelerate the development ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... LONDON, March 2, 2012  ConvaTec, a world-leading developer ... and hospital care today announced that Amcare Ltd, ... has acquired SureCalm Healthcare Holdings Ltd and subsidiaries ... specialises in the home delivery of prescribable stoma ...
... Mich., March 2, 2012 Rubicon Genomics, Inc., ... to improve the capabilities and performance of DNA ... has selected Velesco Pharmaceutical Services to manufacture the ... with Agendia,s breast cancer diagnostics.  Velesco is a ...
Cached Medicine Technology:ConvaTec Announces Acquisition of SureCalm Healthcare 2Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use 2Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use 3
(Date:7/12/2014)... (PRWEB) July 12, 2014 Restore My ... Sen and Samantha Pearson, a couple boasting very impressive ... launch Restore My Vision Today as a way to ... ophthalmologists have become in their respective patients’ treatments ... privy to a “secret” trove of pertinent information relevant ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/12/2014)... Ladies, it doesn't matter what your budget is, ... looking for an affordable gown can visit Discount-Dress.com ... get their dream items. Recently, the company has announced its ... Along with that, it is also providing great discounts for ... the deadline of this promotion is July 29, 2014. ...
(Date:7/11/2014)... Recently, DressyQuinceanera.com, a well-known wedding dress ... dresses to its online category. Furthermore, the firm ... deeply discounted rates, up to 62% off. , The ... excellent in terms of quality and style. All items ... are also offered for the company’s other items: lace ...
(Date:7/11/2014)... (PRWEB) July 12, 2014 According ... the total market is expected to register a ... 2019. , Browse 71 market data tables and ... TOC on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , ... report., http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides ...
Breaking Medicine News(10 mins):Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4
... (HCV) can be transmitted during intravenous (IV) administration of ... , the official journal of the American Gastroenterological Association ... contamination not endoscopy contamination was the cause ... educate the health-care community on the importance of strict ...
... July 22, 2010 (Oakland, Calif.) A total joint ... can enhance patient safety, quality of care, cost-effectiveness and ... and print editions of Clinical Orthopedics and Related ... and Joint Surgeons. Kaiser Permanente,s Total Joint ...
... circumcision has been proposed as a possible HIV prevention strategy ... University of Pittsburgh Graduate School of Public Health presented ... a very small effect on reducing HIV incidence in the ... risk of HIV transmission by removing cells in the foreskin ...
... Reporter , WEDNESDAY, July 21 (HealthDay News) -- Scientists believe ... they say could lead to the first drugs to tame ... are intolerant to the protein gluten, which is found in ... reaction that damages the lining of the small intestine, which ...
... University/University Hospitals Case Medical Center Center for AIDS ... five-year renewal grant from the National Institutes of ... clinical and technological support to researchers working on ... Case Medical Center, MetroHealth Medical Center, Cleveland Clinic, ...
... Reporter , WEDNESDAY, July 21 (HealthDay News) -- A two-step ... arteries and then inserts stem cells to promote healing of ... research suggests. "One of the problems of removing plaque ... damage to the underlying wall," explained Dr. Edward A. Fisher, ...
Cached Medicine News:Health News:Misuse of anesthesia could cause hepatitis virus transmission 2Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2Health News:Study Points to Molecular Origins of Celiac Disease 2Health News:Study Points to Molecular Origins of Celiac Disease 3Health News:$9M NIH grant renewal awarded to Case Western Reserve/UHCMC Center for AIDS Research 2Health News:$9M NIH grant renewal awarded to Case Western Reserve/UHCMC Center for AIDS Research 3Health News:Procedure Rejuvenates Aging Arteries in Pigs 2Health News:Procedure Rejuvenates Aging Arteries in Pigs 3
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® Specialty Tubes - Other - Plastic...
BD Vacutainer® Specialty Tubes - Lead Testing...
Medicine Products: